

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: November 11, 2014  
*(Date of earliest event reported)*

**CELLECTAR BIOSCIENCES, INC.**  
*(Exact name of registrant as specified in its charter)*

**Delaware**  
*(State or other jurisdiction  
of incorporation)*

**333-119366**  
*(Commission  
File Number)*

**04-3321804**  
*(IRS Employer  
Identification Number)*

**3301 Agriculture Drive**  
**Madison, WI 53716**  
*(Address of principal executive offices)*

**(608) 441-8120**  
*(Registrant's telephone number, including area code)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM 7.01 REGULATION FD DISCLOSURE**

On November 11, 2014, we issued a press release announcing recent company highlights and our results for the third quarter and nine months ended September 30, 2014. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.

---

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

(d) Exhibits

Number	Title
99.1	Press release dated November 11, 2014, entitled "Collectar Biosciences Reports Third Quarter 2014 Financial Results and Recent Highlights"

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 12, 2014

**CELLECTAR BIOSCIENCES, INC.**

By: /s/ Chad J. Kolean

Name: Chad J. Kolean

Title: Vice President and Chief Financial Officer

---

**EXHIBIT INDEX**

---

Number	Title
99.1	Press release dated November 11, 2014, entitled "Collectar Biosciences Reports Third Quarter 2014 Financial Results and Recent Highlights"

---



## **Cellecstar Biosciences Reports Third Quarter 2014 Financial Results and Recent Highlights**

*Management to Host Conference Call and Webcast at 5:00 PM EST*

**MADISON, Wis., November 11, 2014** – Cellecstar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, is providing an overview of its development programs and financial results for the third quarter 2014.

### **Recent Highlights:**

- Publication detailing efficacy of Cellecstar's proprietary phospholipid ether (PLE) analog agents for the detection, imaging and real-time visualization of colorectal cancer was published in *PLOS ONE*, an international, peer-reviewed publication
  - U.S. Food & Drug Administration (FDA) accepted the Company's investigational new drug (IND) application to evaluate I-131-CLR1404 in clinical trials in relapsed or refractory multiple myeloma, an incurable cancer of plasma cells
  - Completed underwritten public offering generating gross proceeds of \$13.5 million, before deducting underwriting discounts and commissions and other offering expenses
  - Extinguished all outstanding debt and related accrued interest associated with the February 2014 private placement of convertible debentures in exchange for common shares and warrants in conjunction with the underwritten offering
  - Secured listing of common stock on Nasdaq Capital Market under the ticker CLRB
-

“Over the past few months, we have worked to develop a program that could showcase the potential therapeutic benefit of our highly-targeted, cancer-selective radiopharmaceutical, I-131-CLR1404. We believe relapsed or refractory multiple myeloma not only provides this opportunity but represents a medical need in which we believe our therapeutic could be impactful. With the recent acceptance of our IND, we are now working with our lead investigator and site staff to initiate our first therapeutic trial in this indication,” commented Dr. Simon Pedder, Collectar’s president and chief executive officer. “In addition to progress made across our pipeline during the third quarter, we are pleased to have also significantly strengthened our balance sheet. With this infusion of capital, new Nasdaq listing and a robust line-up of clinical programs, we are well-positioned to make 2015 a transformative year for Collectar.”

**Financial Results for the Quarter and Nine Months Ended September 30, 2014:**

Collectar reported a net loss for the quarter ended September 30, 2014 of \$0.5 million or (\$0.10) per share compared with a net loss of \$1.3 million or (\$0.46) per share reported for the comparable period in 2013. For the first nine months of 2014, Collectar reported a net loss of \$5.5 million or (\$1.54) per share compared to a net loss of \$6.8 million or (\$2.47) per share for the nine months ended September 30, 2013.

Research and development (R&D) expenses for the quarter ended September 30, 2014 were \$1.5 million, compared to \$2.1 million for the third quarter of 2013. For the nine months ended September 30, 2014, Collectar’s research and development expenses were \$4.6 million compared to \$5.3 million during the first nine months of 2013.

Collectar’s general and administrative (G&A) expenses were essentially unchanged year-over-year with third quarter 2014 G&A expenses totaling \$0.8 million. Similarly, G&A expenses for the nine months ended September 30, 2014 were \$2.8 million compared to \$3.0 million for the comparable period in 2013.

Collectar ended the quarter with \$11.6 million in cash and cash equivalents compared to \$2.4 million in cash and cash equivalents at December 31, 2013.

On August 20, 2014, Collectar completed an underwritten offering of shares and warrants that generated new gross proceeds of \$13.5 million. The proceeds of this offering will be used for further research and development of Collectar’s pipeline. Collectar anticipates that the cash and cash equivalents at quarter-end combined with net proceeds from its August offering will fund the company's planned research and development programs into the fourth quarter 2015.

---

**Event Details:**

Interested investors may participate in the conference call by dialing 888-646-8293 (domestic) or 973-453-3065 (international). A replay will be available for one week following the call by dialing 855-859-2056 for domestic participants or 404-537-3406 for international participants and entering conference ID 32168812 when prompted. Participants may also access both the live and archived webcast of the conference call on the investor relations section of Collectar's web site, [www.collectar.com](http://www.collectar.com).

**About Collectar Biosciences, Inc.**

Collectar Biosciences is developing agents to detect, treat and monitor a broad spectrum of cancers. Using a novel phospholipid ether analog (PLE) platform technology as a targeted delivery and retention vehicle, Collectar's compounds are designed to be selectively taken up and retained in cancer cells including cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform, Collectar has developed a portfolio of product candidates engineered to leverage the unique characteristics of cancer cells to "find, treat and follow" malignancies in a highly selective way. I-124-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent currently being evaluated in a Phase II glioblastoma imaging trial. Additionally, multiple investigator-sponsored Phase I/II clinical trials are ongoing across 11 solid tumor indications. I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells including cancer stem cells. A Phase Ib dose-escalation trial of I-131-CLR1404 in patients with advanced solid tumors was completed in the first quarter of 2014 and results presented at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting. CLR1502 is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. For additional information please visit [www.collectar.com](http://www.collectar.com).

---



## **INVESTOR CONTACT**

Kate McNeil, Vice President of IR, PR & Corporate Communications

Cellectar Biosciences, Inc.

Phone: (347) 204-4226

Email: [kmcneil@cellectar.com](mailto:kmcneil@cellectar.com)

This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2013. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

---